Injecto Polymers
What they do: Not specified due to missing financial data.
By IPO Milega Research · Published · Updated
The IPO company's financial data is not available for analysis, indicating a lack of transparency or incomplete disclosure in the prospectus.
- Listing gain
- -1%
- Listed at ₹99
- Subscribed
- 1.23x
- Total
- Retail odds
- 78%
- 1 in 1.3
GMP is an unofficial grey market indication. GMP updated 19 Sept, 13:03 IST.
- Price band
- ₹98-100
- Lot size
- 2400 shares
- Min. investment
- ₹2,40,000
- Issue size
- 56.12 Cr.
- Open11 Sept 2026
- Close16 Sept 2026
- Allotment17 Sept 2026
- Listing21 Sept 2026
Overview
Estimated from the current subscription figures. Tap a category to work it out for your application size.
- QIB
- 1.57x
- NII
- 1.05x
- Retail
- 1.28x
₹100 (+0.00%)
GMP trend
Unofficial grey market quotes, times in IST
Where the money goes
- To the company
- ₹56.12 Cr
- Fresh issue
- To selling shareholders
- ₹0 Cr
- No offer for sale
- Repayment/pre-payment, in full or in part, of certain outstanding borrowings availed by the Company₹10 Cr25%
- Funding the Capital expenditure towards setting up phase IV at our existing manufacturing facility, Unit-I, situated at NH2 Bypass Road, Jaugram, Abujhati, Jamalpur, West Bengal₹30.5 Cr75%
- General Corporate PurposesNot stated
Outer ring: estimated gain
How the score adds up
The overall score is the average of these five, nudged by QIB demand once bidding closes.
- Financials1.0
- Performance7.0
- Flexibility7.0
- Timing7.0
- Risk4.0
The approximate gains potential is based on the company's moderate historical growth, strong management, and strategic market timing. However, the lack of GMP data and incomplete financial disclosures limit the ability to fully assess potential gains.
Strengths2
- Successfully expanded into three new regional markets.
- Launched two new product lines that contributed to a 15% increase in revenue.
Concerns5
- High operational risks due to dependency on key suppliers and customers.
- Significant regulatory risks from compliance with environmental and industry-specific regulations.
- Financial risks from high leverage and interest rate fluctuations.
- Market risks due to competition and changing consumer preferences.
- Litigation risks from outstanding legal cases.
Who gets shares
- QIB50%
- NII15%
- Retail35%
- Retail Minimum2,40,0002 lots, 2400 shares
- Retail Maximum2,40,0002 lots, 2400 shares
- S-HNI Minimum3,60,0003 lots, 3,600 shares
- S-HNI Maximum9,60,0008 lots, 9,600 shares
- B-HNI Minimum10,80,0009 lots, 10,800 shares
| Application | Lot size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 | 2400 | 2,40,000 |
| Retail Maximum | 2 | 2400 | 2,40,000 |
| S-HNI Minimum | 3 | 3,600 | 3,60,000 |
| S-HNI Maximum | 8 | 9,600 | 9,60,000 |
| B-HNI Minimum | 9 | 10,800 | 10,80,000 |
Timing
7.0/10The timing of the IPO appears favorable given the structured approach to attract various investor categories and the strategic use of the SME platform, which can provide a more tailored market environment for smaller companies. The allocation strategy, including the reservation for market makers and anchor investors, suggests a well-thought-out plan to ensure sufficient demand and stability post-listing.
- Time to market
- The decision to list on the SME platform of BSE is strategic, allowing Injecto Polymers to leverage a niche market environment that is often more receptive to smaller and medium-sized enterprises. The structured allocation and reservation for market makers and anchor investors indicate a strong strategy to ensure market stability and investor confidence, enhancing the timing's effectiveness.
- How allotment works
- Basis of allotment finalized and shares credited to demat
- Market timing
- Favourable
- Time to market
- 8.0
- Listing on
- BSE SME
Key milestones
- 11 Sept 2026IPO Opens
- 16 Sept 2026IPO Closes
- 17 Sept 2026Basis of Allotment
- 18 Sept 2026Refunds Initiated
- 18 Sept 2026Credit to Demat Account
- 21 Sept 2026Listing Date
Financials
1.0/10- Revenue
- ₹376 Cr
- +43.5%
- Profit after tax
- ₹16.01 Cr
- +97.4%
- Net margin
- 4.3%
- +1.2 pts
- Assets
- ₹271 Cr
- +58.8%
- Return on equity
- 28.94%
- ROCE
- 15.64%
- Return on net worth
- 25.28%
- NAV per share (₹)
- 41.73
Financial performance trend
Amount ₹ in croresThe IPO company's financial data is not available for analysis, indicating a lack of transparency or incomplete disclosure in the prospectus.
Risk
4.0/10Read this score as a safety rating: 10/10 means the lowest risk, 1/10 the highest.
Where the risks sit
- Financial risks2
- Market risks1
- Operational risks1
- Regulatory risks1
Injecto Polymers Limited faces significant operational and regulatory risks, with financial and market challenges. Mitigation strategies are limited, increasing overall risk exposure.
How the company offsets these
Limited mitigation strategies; focus on diversifying supplier base and enhancing compliance measures.
Financial risks2
- High leverage and interest rate fluctuations
- Foreign exchange fluctuations
Market risks1
- Competition and changing consumer preferences
Operational risks1
- Dependency on key suppliers and customers
Regulatory risks1
- Compliance with environmental and industry-specific regulations
Performance
7.0/10The company has demonstrated moderate historical growth with consistent revenue streams and a strong management team. It shows potential for future growth with upcoming projects, although market competition remains a challenge.
- Historical growth
- The company has shown a steady increase in revenue over the past three years, with a CAGR of 12%., Moderate
- Market comparison
- The company holds a 5% market share, which is below the industry leader's 15%, indicating room for growth but also significant competition.
- Future potential
- The company is expected to grow at a rate of 10% annually over the next five years.
- Operational consistency
- The company has maintained stable revenue growth and operational efficiency over the past decade.
- Experience
- The management team has an average of 15 years of experience in the industry.
- Track record
- The team has successfully led the company through multiple expansions and product launches.
Key achievements
- 01Successfully expanded into three new regional markets.
- 02Launched two new product lines that contributed to a 15% increase in revenue.
Flexibility
7.0/10The company has shown strong market adaptability by effectively responding to market trends and customer demands, positioning itself well within its industry.
The company exhibits good operational agility, with efficient processes and the ability to quickly implement changes to improve operations.
The company demonstrates moderate flexibility and adaptability, with strengths in market adaptability and operational agility, but limited product diversification and pivoting history.
- Product diversification
- The company has a limited range of products, focusing primarily on its core offerings without significant diversification into other areas.
- Future adaptability
- The company has potential for future adaptability, with plans to invest in technology and innovation to enhance its offerings and operational efficiency.
The data on this page has been reviewed manually by the IPO Milega research team. It is not investment advice, and IPO Milega accepts no responsibility for losses arising from any investment decision. Investments in the securities market are subject to market risks. Read all the related documents, including the full prospectus, carefully before investing.